scholarly journals Osteoclastic giant cell variant of urothelial carcinoma in a COVID- positive patient: A rare variant in an unusual circumstances

2021 ◽  
Vol 5 (1) ◽  
pp. 009-011
Author(s):  
Rana Chanchal ◽  
Goel Divya ◽  
Singh Akanksha ◽  
Babu Suresh ◽  
Singh Vishwajeet
Keyword(s):  
Urothelial Carcinoma ◽  
Giant Cell ◽  
Transitional Cell ◽  
Severity Of Illness ◽  
Rare Type ◽  
Histological Variants ◽  
Divergent Differentiation ◽  
Great Propensity ◽  
Cell Variant ◽  
Bladder Carcinomas

Bladder carcinomas have a great propensity for divergent differentiation with more that 90% being Transitional cell carcinoma. Several histological variants have been have described so far; they are not only morphologically unique but also have significant prognostic and therapeutic differences making their timely identification of paramount importance. Osteoclastic giant cell variant of urothelial carcinoma is very rare type with controversial management. Studies from China have documented higher incidence and severity of illness in COVID-19 positive cancer patients. We report an unusual case of Osteoclastic giant cell variant of urothelial carcinoma in a 63 yrs old male patient associated with simultaneous COVID-19 infection.

scholarly journals Clear-cell variant urothelial carcinoma of the bladder: a case report and review of the literature

Rare Tumors ◽  
2012 ◽  
Vol 4 (4) ◽  
pp. 153-155 ◽  
Author(s):  
Mario W. Kramer ◽  
Mahmoud Abbas ◽  
Stefanie Pertschy ◽  
Jan Ulrich Becker ◽  
Hans-Heinrich Kreipe ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Clear Cell ◽  
Transitional Cell ◽  
Tumor Burden ◽  
Initial Diagnosis ◽  
Review Of The Literature ◽  
Peritoneal Carcinosis ◽  
Carcinoma Of The Bladder ◽  
Cell Variant ◽  
Clear Cell Variant

Clear cell variants of transitional cell carcinomas (TCC) of the bladder are extremely rare tumors. Only 6 cases have been reported until now. We report of a 67 year old man who presented with fast growing tumor disease. While initial diagnosis showed localized bladder tumor, final histopathology revealed pT4, G3, L1 urothelial carcinoma with clear cell differentiation. No more than 14 weeks after initial diagnosis the patient died from multi-organ failure after unsuccessful salvage laparotomy which showed massive tumor burden within the pelvis and peritoneal carcinosis. This case demonstrated an extremely fast tumor growth. Therefore, patients with clear cell urothelial carcinoma should be treated vigorously and without time delay. We present a case of clear cell variant of TCC which exhibited an extremely aggressive behavior. To our knowledge this is the fifth report of this rare disease.

scholarly journals Various Histomorphologic Patterns of Urothelial Carcinoma in TURBT Specimen

Esculapio ◽  
2021 ◽  
Vol 16 (4 (oct 2020 - dec 2020)) ◽  
Author(s):  
Hira Kareem ◽  
Amna Jahan ◽  
Iram Nadeem ◽  
Samra Sameen ◽  
Rajia Liaqat ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Transurethral Resection ◽  
Age Groups ◽  
Neuroendocrine Differentiation ◽  
Clinical Implications ◽  
High Grade ◽  
Histological Variants ◽  
Divergent Differentiation ◽  
Resection Specimen ◽  
Nested Variant

Objective: To evaluate the various morphologic patterns of urothelial carcinoma in transurethral resection specimen of urinary bladder. Method: One hundred ninty three biopsies of transurethral resection of bladder from different age groups without exception of sex and race were included in this study from year 2013-2019 in Services Hospital Lahore. Result: Eighty-eight cases from 193 biopsies from services hospital Lahore in 2013 to 2019 were reported as high-grade urothelial carcinoma. While 52out of 193 cases were diagnosed as nested variant of urothelial carcinoma.03 cases neuroendocrine differentiation of urothelial carcinoma is identified and 21 cases having squamous and 12 cases with sarcomatoid differentiation of urothelial carcinoma is reported. Conclusion: Urothelial carcinoma has many histological variants each having different prognosis and clinical implications. So accurate subtyping of the tumor is important for patient's better management. Key Words: Urothelial carcinoma, sarcomatoid, divergent differentiation How to Cite: Kareem H, Jahan A, Nadeem I, Sameen S, Liaqat R, Liaquat T. Various histomorphologic patterns of urothelial carcinoma in TURBT specimen. Esculapio.2020;16(04):66-69.

Safety of Vinflunine in Patients with Advanced Urothelial Carcinoma Refractory to Platinum-based Chemotherapy: A Prospective Pilot Study

2019 ◽  
Vol 14 (1) ◽  
pp. 31-36
Author(s):  
Raafat Abdel-Malek ◽  
Kyrillus S. Shohdy ◽  
Noha Abbas ◽  
Mohamed Ismail ◽  
Emad Hamada ◽  
...  
Keyword(s):  
Pilot Study ◽  
Adverse Events ◽  
Urothelial Carcinoma ◽  
Transitional Cell ◽  
Chemotherapeutic Agents ◽  
Serious Adverse Events ◽  
Platinum Based Chemotherapy ◽  
Number Of Patients ◽  
Advanced Urothelial Carcinoma ◽  
Grade 3

Background: Several single chemotherapeutic agents have been evaluated as the second-line treatment of advanced urothelial carcinoma. Despite encouraging efficacy outcomes, toxicity has often led to dose modifications or discontinuation. We aimed to assess the safety of vinflunine in a particular population of advanced transitional cell carcinoma of urothelium (TCCU), that were exposed to the previous toxicity of chemotherapy. Methods: This is an open-label, prospective, single-center pilot study to evaluate the response rate and safety profile of vinflunine in patients with advanced TCCU. It was planned to enroll 25 evaluable patients. Eligible patients are those with progressive disease after first-line platinum-based regimen for advanced or metastatic disease. Results: The study was prematurely closed due to two sudden deaths that were judged by the review board as treatment-related. Only ten patients were evaluated and received at least one cycle of vinflunine. All but one were male and seven underwent radical surgery. Eight had a distant metastasis (mainly lung and/or liver). Disease control rate was 40%, four patients had a partial response with median duration of response of 3.5 months. The median overall survival was 3.2 months (95% CI:1.67- 4.73). There were three serious adverse events namely two sudden deaths and one grade 4 thrombocytopenia. Nine grade 3/4 adverse events occurred. The most common all-grade adverse events were fatigue (50%), constipation (40%) and vomiting (40%). Moreover, grade 3 fatigue occurred in 30% of patients. Only one patient, who achieved PR for 5 months, was fit to receive further cytotoxic chemotherapy. Conclusion: The activity of vinflunine in advanced urothelial carcinoma came at the expense of its safety. The use of vinflunine has to be limited to the selected group of patients. However, this is a single institute experience in a limited number of patients.

scholarly journals Systematic Review of the Role of BCG in the Treatment of Urothelial Carcinoma of the Prostatic Urethra

2021 ◽  
pp. 1-8
Author(s):  
Oliver Patschan ◽  
Philippe E. Spiess ◽  
George N. Thalmann ◽  
Joan Palou Redorta ◽  
Georgios Gakis
Keyword(s):  
Side Effects ◽  
Urothelial Carcinoma ◽  
Evidence Synthesis ◽  
Tnm Classification ◽  
Transitional Cell ◽  
Prostatic Urethra ◽  
Local Response ◽  
Pubmed Database ◽  
Bcg Therapy ◽  
Tumor Stages

BACKGROUND: In patients with non-invasive urothelial carcinoma of the prostatic urethra (PUC), treatment with Bacillus Calmette-Guárin (BCG) could be beneficial. OBJECTIVE: To assess the response rates to BCG in the different tumor stages, to describe the clinical impact of transurethral resection of the prostate (TURP) before BCG treatment, and to review the side effects of BCG treatment for PUC. METHODS: A systematic search was conducted using the PubMed database to identify original studies between 1977 and 2019 reporting on PUC and BCG. RESULTS: Of a total of 865 studies, ten were considered for evidence synthesis. An indication for BCG treatment was found in non-stromal invasive stages (Tis pu, Tis pd) and in stromal infiltrating cases (T1) of primary and secondary PUC when transitional cell carcinoma was the histology of origin. Studies including patients treated with TURP before BCG showed a better local response in the prostatic urethra with a higher DFS (80–100% vs. 63–89%) and PFS (90–100% vs. 75–94%) than patients in studies in which no TURP was performed. However, this difference in recurrence and progression in the prostate neither affected the total PFS (57–75% vs. 58–93%), nor the disease specific survival (70–100% vs. 66–100%). CONCLUSIONS: The use of resection loop biopsies of the prostatic urethra in appropriate cases during the primary work-up for suspected PUC, as well as the use of the current TNM classification for PUC, need to be improved. BCG therapy for non-stromal invasive stages of PUC show a good local response. Local response is further improved by a TURP before BCG therapy, although the overall prognosis does not seem to be affected. Further evidence for BCG treatment in the rare cases of stromal invasive PUC is needed. Specific side effects of BCG treatment for PUC are not reported.

scholarly journals Clinicopathological characteristics of ypT0N0 urothelial carcinoma following neoadjuvant chemotherapy and cystectomy

2019 ◽  
Vol 72 (8) ◽  
pp. 550-553 ◽  
Author(s):  
Martin J Magers ◽  
Hristos Z Kaimakliotis ◽  
Marcelo P Barboza ◽  
Elhaam Bandali ◽  
Nabil Adra ◽  
...  
Keyword(s):  
Foreign Body ◽  
Neoadjuvant Chemotherapy ◽  
Urothelial Carcinoma ◽  
Giant Cell ◽  
Chronic Inflammation ◽  
Morphological Features ◽  
Foreign Body Giant Cell ◽  
Cell Reaction ◽  
Variant Histology

AimsTo describe a large tertiary care academic centre’s experience with patients who achieve a complete pathological response (ie, ypT0N0) following neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) with emphasis on morphological features present in the RC and clinical outcome.Methods41 patients with ypT0N0 disease following transurethral resection of bladder tumour (TURBT), NAC and RC with available clinical follow-up information were analysed. Slides from all RCs were reviewed to confirm pathological stage and assess for morphological parameters (eg, foreign body giant cell reaction, dystrophic calcification, scar and fat necrosis).ResultsWith median follow-up of 32.8 months, the recurrence-free survival at 1 and 5 years was 97.4% and 93.5%, while the overall survival at 3 and 5 years was 94.2% and 88.6%, respectively. No patients died of urothelial carcinoma. Stage assigned at TURBT was 1 pTa (2%), 1 pT1 (2%), 38 pT2 (93%) and 1 pT3a (2%). 17 TURBTs demonstrated variant histology, with the majority of these being squamous (65%). The most common morphological features present at RC were scar (100%), foreign body giant cell reaction (80%), chronic inflammation within lamina propria (68%) and dystrophic calcifications (39%). Other morphological features were less common or absent.ConclusionypT0N0 disease at RC portends an excellent prognosis, regardless of stage or variant histology in the TURBT; scar, foreign body giant cell reaction, chronic inflammation and dystrophic calcifications are often present.

High-grade Urothelial Carcinoma with Malignant Melanocytic Differentiation

2021 ◽  
pp. 106689692110004
Author(s):  
Hongzhi Xu ◽  
Elizabeth M. Genega ◽  
Liyan Zhuang ◽  
Ming Zhou
Keyword(s):  
Urothelial Carcinoma ◽  
Bladder Wall ◽  
Minor Component ◽  
Asian Woman ◽  
High Grade ◽  
Therapeutic Implications ◽  
Divergent Differentiation ◽  
Rare Cells ◽  
A Minor ◽  
Melanocytic Differentiation

Urothelial carcinoma usually shows divergent differentiation and variant histology with squamous and glandular morphology being most common. In this report, we present a case of divergent malignant melanocytic differentiation in a high-grade urothelial carcinoma. A 98-year-old East Asian woman with an anterior bladder wall mass underwent resection, which revealed a high-grade poorly differentiated tumor. A minor component of high-grade papillary urothelial carcinoma and carcinoma in situ is also present. The majority of the tumor cells are morphologically and immunohistochemically consistent with melanoma, a minority of cells are positive for urothelial markers, and rare cells coexpress both melanocytic and urothelial markers. Cells that express melanocytic markers or urothelial markers are intimately admixed together. Taken together, a diagnosis of high-grade urothelial carcinoma with malignant melanocytic differentiation was rendered. This is the first report in the literature of malignant melanocytic differentiation in a high-grade urothelial carcinoma, a finding that may have important diagnostic and therapeutic implications.

Microcystic Transitional Cell Carcinoma

2002 ◽  
Vol 126 (7) ◽  
pp. 859-861 ◽  
Author(s):  
Xavier Leroy ◽  
Emmanuelle Leteurtre ◽  
Alexandre De La Taille ◽  
David Augusto ◽  
Jacques Biserte ◽  
...  
Keyword(s):  
Transitional Cell Carcinoma ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Renal Pelvis ◽  
Transitional Cell ◽  
Macroscopic Hematuria ◽  
Computed Tomographic ◽  
First Case ◽  
History Of ◽  
Invasive Transitional Cell Carcinoma

Abstract Microcystic transitional cell carcinoma is a rare variant of urothelial carcinoma; to date, it has been described only in the urinary bladder. We report 2 cases of microcystic transitional cell carcinoma arising in the renal pelvis. The first case occurred in a 73-year-old man with a history of superficially invasive transitional cell carcinoma who presented with macroscopic hematuria and anemia. The second case occurred in a 62-year-old woman who had no relevant medical history and presented with hematuria. Computed tomographic scan revealed a tumor of the renal pelvis. In both cases, microscopic examination showed invasive transitional cell carcinoma with prominent cystic features. The cysts were irregular in size and were deeply infiltrative. The cysts were lined by single or multiple layers of cuboidal or flattened cells with minimal cytological atypia. The first patient died of his disease 18 months after presentation. The second patient remained well at her 6-month follow-up examination. Microcystic transitional cell carcinoma is an unusual, deceptively bland variant of urothelial carcinoma, which can mimic benign lesions.

Urothelial carcinoma (clear cell variant) diagnosed with useful immunohistochemistry stain

2006 ◽  
Vol 13 (11) ◽  
pp. 1448-1450 ◽  
Author(s):  
RYO YAMASHITA ◽  
RAIZOU YAMAGUCHI ◽  
KEIJI YUEN ◽  
MASASHI NIWAKAWA ◽  
KENICHI TOBISU
Keyword(s):  
Urothelial Carcinoma ◽  
Clear Cell ◽  
Cell Variant ◽  
Immunohistochemistry Stain ◽  
Clear Cell Variant

scholarly journals Urothelial bladder carcinoma with major clinical presentation as overactive bladder, without hematuria: case report and literature review

2018 ◽  
Vol 7 (10) ◽  
pp. 4292
Author(s):  
Alexander de J. Rafaelano M. ◽  
Junior J. Araiza Navarro ◽  
María Isabel Tolentino Sosa ◽  
Fernando López Reyes ◽  
Marlene De la Peña Gutiérrez
Keyword(s):  
Bladder Cancer ◽  
Case Report ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Transitional Cell ◽  
The United States ◽  
Transitional Epithelium ◽  
Common Symptom ◽  
Macroscopic Hematuria ◽  
Adjacent Structures

The urothelial carcinoma is the most common type of bladder cancer, comprising approximately 90% of cases in the United States. The most common symptom of bladder cancer is macroscopic hematuria, increased urinary frequency, urgency, or irritative symptoms may occur. Generally, occurs in elderly people, about 9 out of 10 people are over 55 years old, with the average age at diagnosis of 73 years. Males are more likely than women to have this neoplasm with a probability of 1 in 27 (for women the probability is 1 in 89). Most bladder cancers begin in the inner layer, also called the urothelium or transitional epithelium. As it advances, it invades the layers of the bladder and can invade adjacent structures, often metastasizing to distant lymph nodes, bones, lungs or the liver. Among the cancers that originate in the bladder authors have: Urothelial carcinoma (transitional cell carcinoma), squamous cell carcinoma, adenocarcinoma, small cell carcinoma, sarcoma. Hematuria occurs in the majority of patients with urothelial carcinoma. Symptoms such as dysuria, frequency, urgency and pain may also occur, or it may also be asymptomatic.  In this case report, an atypical presentation of bladder cancer is shown, simulating the symptomatology of a Hyperactive Bladder Syndrome.

Sign in / Sign up

Export Citation Format

Share Document